Genetic Disease Factors

-- Test Associated with Changes in Treatment Management in 65% of Patients with Difficult-to-Diagnose Cancers -- REDWOOD CITY, Calif. -- Pathwork Diagnostics, Inc., a pioneer in creating genomics-based diagnostics in oncology utilizing their...

Developing therapeutics using novel biology to selectively activate genes CAMBRIDGE, Mass. -- RaNA Therapeutics, Inc. today announced it has completed a $20.7 million round of financing co-led by Atlas Venture, SR One, and...

Carlsbad-based Isis Pharmaceuticals Inc. said it has entered into agreement with biotechnology giant Biogen Idec of Weston, Mass., to develop and commercialize an investigational drug for a rare genetic disorder known as spinal...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/d990a7/product_profiles) has announced the addition of the "Product Profiles: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation" report to their offering. The targeted therapies...

TAMPA, Fla. & MINNEAPOLIs -- Biovest International, Inc. (OTCQB: "BVTI"), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI"), today announced that Biovest has entered into a key Research Agreement with the Max...

The Montreal Heart Institute will work with GnuBIO to develop a genetic sudden cardiac death screening panel in order to predict risk in patients CAMBRIDGE, Mass. -- GnuBIO, Inc. (GnuBIO), www.gnubio.com a pioneer...

Program Provides GenomeQuest Software, Services, and Expertise to Convert and Consolidate Sanger Gene Test Panels WESTBOROUGH, Mass. -- GenomeQuest Inc., a global provider of large-scale genomic software applications, announced today that it has...

Fifth Partnership Will Help Translate Cancer Genomic Science to Clinical Results CAMBRIDGE, Mass. -- Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genome analysis to routine clinical care, today announced...

- Partnership Includes US Profit Share and Co-Promotion Option for Epizyme - CAMBRIDGE, Mass. -- Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced...

Knome's informatics and software tools to be used to interpret whole genomes of African American and African Caribbean asthma patients CAMBRIDGE, Mass. -- Knome, Inc., the human genome interpretation company, today announced that...

WALTHAM, Mass. -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis H. Bender will present at the Biotech Showcase[TM] 2012 at the Wyndham Parc 55 Hotel, 55 Cyril Magnin Street in...

Study Presented at AACR - IASLC Joint Conference REDWOOD CITY, Calif. -- Pathwork Diagnostics, Inc., a pioneer in creating genomics-based diagnostics in oncology utilizing their proprietary informatics platform, announced today that results from...

SAN FRANCISCO -- Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and...

Dr. David Goldstein and Dr. Yaniv Erlich bring genomics expertise as company pursues future growth CAMBRIDGE, Mass. -- Knome, Inc., the human genome interpretation company, today announced that it has expanded its scientific...

Collaboration to further validate the performance of RainDance's HLASeq[TM] Research Screening Panel LEXINGTON, Mass. -- RainDance Technologies, Inc., the Digital Biology[TM] Company, today announced that it is collaborating with the Hypital Saint-Louis in...

BOULDER, Colo. -- MiRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that William S. Marshall, Ph.D., President...

Investigational BAX 855 is based on ADVATE Factor VIII Molecule DEERFIELD, Ill. -- Baxter International Inc. (NYSE: BAX) today announced the dosing of the first patients in a Phase I clinical trial of...

- RNAi Therapeutic Achieves Robust Silencing of PCKS9 and Reductions of Over 50% in LDL Cholesterol, a Validated Clinical Endpoint - - Results Highlight Major Potency Improvements of Second-Generation Lipid Nanoparticle Platform in...

-- Biogen Idec has Option to Develop and Commercialize Promising Compound for Most Common Genetic Cause of Infant Mortality -- -- Biogen Idec's Expertise in Neurology to Aid in Rapid Development of ISIS-SMN...